Document:

Form of Intellectual Property Agreement

 EXHIBIT 10.6 
 INTELLECTUAL PROPERTY SECURITY AGREEMENT 
 THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of
September 19, 2008, is made by Biovest International, Inc., a Delaware corporation (“Grantor”), in favor of the holders of the Grantor’s 15% Convertible Debentures due March 31, 2010 in the original aggregate
principal amount not to exceed $5,000,000 (each as amended, modified, supplemented and/or restated from time to time, collectively, the “Debentures”) signatory hereto, their endorsees, transferees and assigns (the “Secured
Parties”). 
 W I T N E S S E T H: 
 WHEREAS, pursuant to the Debentures the Secured Parties provide or will provide certain financial accommodations to the Grantor; and 
 WHEREAS, Secured Parties are willing to purchase one or more Debentures, but only upon the condition, among others, that Grantor shall have executed and delivered to the Secured Parties, this Intellectual Property
Security Agreement; 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, Grantor hereby agrees as follows: 
 1. DEFINED TERMS. All
capitalized terms used but not otherwise defined herein shall have the meanings given to them in that certain Security Agreement dated as of the date hereof (as amended, modified, supplemented and/or restated from time to time) among the Grantor and
Secured Parties. 
 2. GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL. To secure the complete and timely payment of
all the Obligations of Grantor now or hereafter existing from time to time, Grantor hereby pledges and grants to Secured Parties a continuing first priority security interest in all of Grantor’s right, title and interest in, to and under the
following, whether presently existing or hereafter created or acquired (collectively, the “Intellectual Property Collateral”): 
 (a) all of its Patents and Patent Licenses to which it is a party including those referred to on Schedule I hereto; 
 (b) all of
its Trademarks and Trademark Licenses to which it is a party including those referred to on Schedule II hereto; 
 (c) all of its Copyrights
and Copyright Licenses to which it is a party including those referred to on Schedule III hereto; 
 (d) all reissues, continuations or
extensions of the foregoing; 

 (e) all goodwill of the business connected with the use of, and symbolized by, each Patent, each Patent
License, each Trademark, each Trademark License, each Copyright and each Copyright License; and 
 (f) all products and proceeds of the
foregoing, including, without limitation, any claim by Grantor against third parties for past, present or future (i) infringement or dilution of any Patent or Patent licensed under any Patent License, (ii) injury to the goodwill associated
with any Patent or any Patent licensed under any Patent License, (iii) infringement or dilution of any Trademark or Trademark licensed under any Trademark License, (iv) injury to the goodwill associated with any Trademark or any Trademark
licensed under any Trademark License, (v) infringement or dilution of any Copyright or Copyright licensed under any Copyright License, and (vi) injury to the goodwill associated with any Copyright or any Copyright licensed under any
Copyright License. 
 3. REPRESENTATIONS AND WARRANTIES. Grantor represents and warrants that Grantor does not have any interest in,
or title to, any Patent, Trademark or Copyright except as set forth in Schedule I, Schedule II and Schedule III, respectively, hereto. This Intellectual Property Security Agreement is effective to create a valid and continuing lien in favor of the
Secured Parties in all of Grantor’s Patents, Trademarks and Copyrights enforceable as such as against any and all creditors of, and purchasers from, Grantor. Upon filing of this Intellectual Property Security Agreement with the United States
Patent and Trademark Office, the United States Copyright Office and the filing of appropriate financing statements with the Secretary of State for the State of Delaware, all action necessary or desirable to protect and perfect Secured Parties’
lien on Grantor’s Patents, Trademarks and Copyrights shall have been duly taken. 
 4. COVENANTS. Grantor covenants and agrees
with Secured Parties that from and after the date of this Intellectual Property Security Agreement and until the Termination Date: 
 (a)
Grantor shall notify Secured Parties immediately if it knows or has reason to know that any application or registration relating to any Patent, Trademark or Copyright (now or hereafter existing) may become abandoned or dedicated, or of any adverse
determination or development (including the institution of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office, the United States Copyright Office or any court) regarding Grantor’s
ownership of any Patent, Trademark or Copyright, its right to register the same, or to keep and maintain the same. 
 (b) In no event shall
Grantor, either directly or through any agent, employee, licensee or designee, file an application for the registration of any Patent, Trademark or Copyright with the United States Patent and Trademark Office, the United States Copyright Office or
any similar office or agency without giving Secured Parties prior written notice thereof, and, upon request of any Secured Party, Grantor shall execute and deliver a supplement hereto (in form and substance satisfactory to such Secured Party) to
evidence Secured Party’s lien on such Patent, Trademark or Copyright, and the general intangibles of Grantor relating thereto or represented thereby. 
 (c) Unless an application or registration is not material to Grantor’s business as determined by Grantor in the exercise of its reasonable business judgment, Grantor shall take 

  

 2 

 
all actions necessary or requested by any Secured Party to maintain and pursue each application, to obtain the relevant registration and to maintain the
registration of each of the Patents or Trademarks (now or hereafter existing), including the filing of applications for renewal, affidavits of use, affidavits of noncontestability and opposition and interference and cancellation proceedings.

 (d) In the event that any of the Intellectual Property Collateral is infringed upon, or misappropriated or diluted by a third party,
Grantor shall notify Secured Parties promptly after Grantor learns thereof. Grantor shall, unless it shall reasonably determine that such Intellectual Property Collateral is in no way material to the conduct of its business or operations, promptly
sue for infringement, misappropriation or dilution and to recover any and all damages for such infringement, misappropriation or dilution, and shall take such other actions any Secured Party shall deem appropriate under the circumstances to protect
such Intellectual Property Collateral. 
 5. SECURITY AGREEMENT. The security interests granted pursuant to this Intellectual Property
Security Agreement are granted in conjunction with the security interests granted to Secured Parties in connection with the transactions contemplated by that certain Securities Purchase Agreement dated as of the date hereof (as amended, modified,
supplemented and/or restated from time to time, the “Purchase Agreement”). Grantor hereby acknowledges and affirms that the rights and remedies of Secured Parties with respect to the security interest in the Intellectual Property
Collateral made and granted hereby are more fully set forth in the Purchase Agreements and the Transaction Documents referred to therein, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

 6. REINSTATEMENT. This Intellectual Property Security Agreement shall remain in full force and effect and continue to be effective
should any petition be filed by or against Grantor for liquidation or reorganization, should Grantor become insolvent or make an assignment for the benefit of any creditor or creditors or should a receiver or trustee be appointed for all or any
significant part of Grantor’s assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced
in amount, or must otherwise be restored or returned by any obligee of the Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment or performance had not been made. In
the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned. 
 7. NOTICES. Whenever it is provided herein that any notice, demand, request, consent, approval, declaration or other communication shall or may be
given to or served upon any of the parties by any other party, or whenever any of the parties desires to give and serve upon any other party any communication with respect to this Intellectual Property Security Agreement, each such notice, demand,
request, consent, approval, declaration or other communication shall be in writing and shall be given in the manner, and deemed received, as provided for in the Purchase Agreement. 
  

 3 

 8. TERMINATION OF THIS SECURITY AGREEMENT. Subject to Section 6 hereof, this Intellectual
Property Security Agreement shall terminate upon the indefeasible payment in full in cash of the Obligations. 
 [Signatures appear on the
following page.] 
  

 4 

 IN WITNESS WHEREOF, Grantor has caused this Intellectual Property Security Agreement to be executed and
delivered by its duly authorized officer as of the date first set forth above. 
  

			
	BIOVEST INTERNATIONAL, INC.
		
	By:	 	  

	Name:	 	Steven Arikian, M.D.
	Title:	 	Chairman and CEO

  

	
	ACCEPTED and ACKNOWLEDGED by:
	
	  

  

			
	By:	 	  

	Name:	 	
	Title:	 	

 Schedule I 
 A. Patents Issued 
  

							
	 COUNTRY
	  	 TITLE
	  	PATENT NO.	  	 ISSUE DATE

	U.S.	  	MULTI-BIOREACTOR HOLLOW FIBER CELL PROPOGATION SYSTEM AND METHOD	  	5,656,421	  	August 12, 1997
				
	U.S.	  	BASKET-TYPE BIOREACTOR	  	5,998,184	  	December 7, 1999
				
	U.S.	  	CELL CULTURE APPARATUS	  	5,416,022	  	May 16, 1995
				
	U.S.	  	PRESSURE CONTROL SYSTEM FOR A BIOREACTOR	  	5,330,915	  	July 19, 1994
				
	U.S.	  	METHOD OF CULTURING LEUKOCYTES	  	5,541,105	  	July 30, 1996
				
	U.S.	  	IMMUNOTHERAPY PROTOCOL OF CULTURING LEUKOCYTES IN THE PRESENCE OF INTERLEUKIN-2 IN A HOLLOW FIBER CARTRIDGE	  	5,631,006	  	May 20, 1997
				
	U.S.	  	MICRO HOLLOW FIBER BIOREACTOR	  	6,001,585	  	December 14, 1999

 Schedule I 
 B. Patents Applications 
 Extra-Capillary Fluid Cycling System and Method for a Cell Culture Device: 
     PCT App. No. PCT/US07/12053, filed 5/21/07 
 Interface of a Cultureware Module in a Cell Culture System and Installation Method Thereof: 
     PCT App. No. PCT/US07/12052,
filed 5/21/07 
 Media Circulation System for a Cell Cultureware Module: 
     PCT App. No. PCT/US07/12054, filed 5/21/07 
 Method and System for the Production of Cells and Cell Products and
Application Thereof: 
     PCT App. No. PCT/US07/12042, filed 5/21/07 
 Rotary Actuator Valve for a Cell Culture System: 
     PCT App. No. PCT/US07/12051, filed 5/21/07

 Method and Apparatus for Purification of a Protein: 
     Provisional App. No. 61/049,692, filed May 1, 2008 
 Integraded System and Method for Growth and Maintenance of
Cells and Collection and Purification of Cell Products: 
     Provisional App. No. 61/049,702, filed May 1, 2008 

 Schedule I 
 C. Patents Licenses 
 Sublicense Agreement between Revimmune, LLC and Biovest International, Inc.,
effective January 16, 2008 
 License Agreement between Biovest International, Inc. and Autovaxid, Inc., effective December 8, 2006

 Schedule II 
 A. Trademark Registrations 
  

									
	 COUNTRY
	  	 TRADEMARK
	  	REG. NO.	  	 REG. DATE
	  	 RENEWAL DATE

	U.S.	  	ACUSYST – MAXIMIZER	  	2379677	  	August 22, 2000	  	
					
	U.S.	  	ACUSYST – XCELL	  	2379695	  	August 22, 2000	  	
					
	EU	  	BIOVEST	  	4239422	  	January 13, 2005	  	
					
	U.S.	  	BIOVAXID	  	3112639	  	December 29, 2003	  	
					
	EU	  	BIOVAXID	  	3605698	  	April 26, 2005	  	

 Schedule II 
 B. Trademark Applications 
  

							
	 COUNTRY
	  	 TRADEMARK
	  	SERIAL NO.	  	 FILE DATE

	U.S.	  	BIOVEST	  	78449977	  	July 13, 2004
	U.S.	  	BIOVEST	  	78449968	  	July 13, 2004
	U.S.	  	BIOVEST	  	78449930	  	July 13, 2004
	CA	  	BIOVAXID	  	1203189	  	January 12, 2004

 Schedule II 
 C. Trademark Licenses 
 None. 

 Schedule III 
 A. Copyright Registrations 
 None. 

 Schedule III 
 B. Copyright Applications 
 None. 

 Schedule III 
 C. Copyright Licenses 
 None.Form of Subordination Agreement

 EXHIBIT 10.7 
 SUBORDINATION AGREEMENT 
 This Subordination Agreement (this “Agreement”) is entered
into as of the 19th day of September 2008, by and among Accentia Biopharmaceuticals, Inc., a Florida corporation (the “Subordinated Lender”), and each of the parties which have executed this Agreement on the signature pages
below as senior lenders (each, a “Senior Lender” and, collectively, the “Senior Lenders”). Unless otherwise defined herein, capitalized terms used herein shall have the meaning provided such terms in the Securities
Purchase Agreement referred to below. 
 BACKGROUND 
 WHEREAS, it is a condition to each Senior Lender’s agreement to continue to make investments in Biovest International, Inc., a Delaware corporation (the “Company”) pursuant to, and in accordance
with, (i) that certain Securities Purchase Agreement, dated as of the date hereof (as amended, modified or supplemented from time to time, the “Purchase Agreement”), among the Company and the Senior Lenders, and (ii) the
Transaction Documents referred to in the Purchase Agreement, that the Subordinated Lender enter into this Agreement. 
 WHEREAS, the
Subordinated Lender has made or will make loans to the Company. 
 NOW, THEREFORE, the Subordinated Lender and the Senior Lenders hereby
agree as follows: 
 TERMS 
 1.
All obligations of the Company and/or any of its Subsidiaries to any Senior Lender, howsoever created, arising or evidenced, whether direct or indirect, absolute or contingent or now or hereafter existing, or due or to become due are referred to as
“Senior Liabilities”. Any and all loans made by the Subordinated Lender to the Company and/or any of its Subsidiaries, together with all other obligations (whether monetary or otherwise) of the Company and/or any of its Subsidiaries to the
Subordinated Lender (in each case, including any interest, fees or penalties related thereto), howsoever created, arising or evidenced, whether direct or indirect, absolute or contingent or now or hereafter existing, or due or to become due are
referred to as “Junior Liabilities”. It is expressly understood and agreed that the term “Senior Liabilities”, as used in this Agreement, shall include, without limitation, any and all interest, fees and penalties accruing on any
of the Senior Liabilities after the commencement of any proceedings referred to in paragraph 4 of this Agreement, notwithstanding any provision or rule of law which might restrict the rights of any Senior Lender, as against the Company, its
Subsidiaries or anyone else, to collect such interest, fees or penalties, as the case may be. 

 2. Except as expressly otherwise provided in this Agreement or as the Senior Lenders may otherwise
expressly consent in writing, the payment of the Junior Liabilities shall be postponed and subordinated in right of payment and priority to the payment in full of all Senior Liabilities. Furthermore, whether directly or indirectly, no payments or
other distributions whatsoever in respect of any Junior Liabilities shall be made (whether at stated maturity, by acceleration or otherwise), nor shall any property or assets of the Company or any of its Subsidiaries be applied to the purchase or
other acquisition or retirement of any Junior Liability until such time as the Senior Liabilities have been indefeasibly paid in full. 
 3.
The Subordinated Lender hereby subordinates all claims and security interests it may have against, or with respect to, any of the assets of the Company and/or any of its Subsidiaries (the “Subordinated Lender Liens”), to the
security interests granted by the Company and/or any of its Subsidiaries to each Senior Lender in respect of the Senior Liabilities. No Senior Lender shall owe any duty to the Subordinated Lender as a result of or in connection with any Subordinated
Lender Liens, including, without limitation, any marshalling of assets or protection of the rights or interests of the Subordinated Lender. The Senior Lenders shall have the exclusive right to manage, perform and enforce the underlying terms of the
Purchase Agreements, the Transaction Documents and each other document, instrument and agreement executed from time to time in connection therewith (collectively, the “Security Agreements”) relating to the assets of the Company and
its Subsidiaries and to exercise and enforce its rights according to its discretion. The Subordinated Lender waives all rights to affect the method or challenge the appropriateness of any action taken by any Senior Lenders in connection with any
Senior Lender’s enforcement of its rights under the Security Agreements. Only the Senior Lenders shall have the right to restrict, permit, approve or disapprove the sale, transfer or other disposition of the assets of the Company or any of its
Subsidiaries. As between each Senior Lender and the Subordinated Lender, the terms of this Agreement shall govern even if all or part of any Senior Lender’s liens are avoided, disallowed, set aside or otherwise invalidated. 
 4. In the event of any dissolution, winding up, liquidation, readjustment, reorganization or other similar proceedings relating to the Company and/or any
of its Subsidiaries or to its creditors, as such, or to its property (whether voluntary or involuntary, partial or complete, and whether in bankruptcy, insolvency or receivership, or upon an assignment for the benefit of creditors, or any other
marshalling of the assets and liabilities of the Company and/or any of its Subsidiaries, or any sale of all or substantially all of the assets of the Company and/or any of its Subsidiaries, or otherwise), the Senior Liabilities shall first be
irrevocably paid in full before the Subordinated Lender shall be entitled to receive and to retain any payment, distribution, other rights or benefits in respect of any Junior Liability. In order to enable each Senior Lender to enforce its rights
hereunder in any such action or proceeding, each Senior Lender is hereby irrevocably authorized and empowered in its discretion as attorney in fact for the Subordinated Lender to make and present for and on behalf of the Subordinated Lender such
proofs of claims against the Company and/or its Subsidiaries as the Senior Lenders may deem expedient or proper and to vote such proofs of claims in any such proceeding and to receive and collect any and all dividends or other payments or
disbursements made thereon in whatever form the same may be paid or issued and to apply same on account of any the Senior Liabilities. In the event, prior to indefeasible payment in full of the Senior Liabilities, the Subordinated Lender shall
receive any payment in respect of the Junior Liabilities and/or in 

  

 2 

 
connection with the enforcement of the Subordinated Lender’s rights and remedies against the Company and/or any of its Subsidiaries, whether arising in
connection with the Junior Liabilities or otherwise, then the Subordinated Lender shall forthwith deliver, or cause to be delivered, the same to the Senior Lenders in precisely the form held by the Subordinated Lender (except for any necessary
endorsement) and until so delivered the same shall be held in trust by the Subordinated Lender as the property of the Senior Lender. 
 5.
The Subordinated Lender will mark its/his books and records so as to clearly indicate that its/his respective Junior Liabilities are subordinated in accordance with the terms of this Agreement. The Subordinated Lender will execute such further
documents or instruments and take such further action as any Senior Lender may reasonably request from time to time to carry out the intent of this Agreement. 
 6. The Subordinated Lender hereby waives all diligence in collection or protection of or realization upon the Senior Liabilities or any security for the Senior Liabilities. 
 7. The Subordinated Lender will not, without the prior written consent of each of the Senior Lenders: (a) attempt to enforce or collect any Junior
Liability or any rights in respect of any Junior Liability; or (b) commence, or join with any other creditor in commencing, any bankruptcy, reorganization or insolvency proceedings with respect to the Company and/or any of its Subsidiaries.

 8. Each Senior Lender may, from time to time, at its sole discretion and without notice to the Subordinated Lender, take any or all of the
following actions: (a) retain or obtain a security interest in any property to secure any of the Senior Liabilities; (b) retain or obtain the primary or secondary obligation of any other obligor or obligors with respect to any of the
Senior Liabilities; (c) extend or renew for one or more periods (whether or not longer than the original period), alter, increase or exchange any of the Senior Liabilities, or release or compromise any obligation of any nature of any obligor
with respect to any of the Senior Liabilities; and (d) release its security interest in, or surrender, release or permit any substitution or exchange for, all or any part of any property securing any of the Senior Liabilities, or extend or
renew for one or more periods (whether or not longer than the original period) or release, compromise, alter or exchange any obligations of any nature of any obligor with respect to any such property. 
 9. The Senior Lenders, may, from time to time, whether before or after any discontinuance of this Agreement, without notice to the Subordinated Lender,
assign or transfer any or all of the Senior Liabilities or any interest in the Senior Liabilities; and, notwithstanding any such assignment or transfer or any subsequent assignment or transfer of the Senior Liabilities, such Senior Liabilities shall
be and remain Senior Liabilities for the purposes of this Agreement, and every immediate and successive assignee or transferee of any of the Senior Liabilities or of any interest in the Senior Liabilities shall, to the extent of the interest of such
assignee or transferee in the Senior Liabilities, be entitled to the benefits of this Agreement to the same extent as if such assignee or transferee were a Senior Lender, as applicable; provided, however, that, unless the Senior Lenders shall
otherwise consent in writing, the Senior Lenders shall have an unimpaired right, prior and superior to that of any such assignee or transferee, to enforce this Agreement, for the benefit of the Senior Lenders, as to those of the Senior Liabilities
which the Senior Lenders have not assigned or transferred. 
  

 3 

 10. The Senior Lenders shall not be prejudiced in their rights under this Agreement by any act or failure
to act of the Subordinated Lender, or any noncompliance of the Subordinated Lender with any agreement or obligation, regardless of any knowledge thereof which any Senior Lender may have or with which any Senior Lender may be charged; and no action
of any Senior Lender permitted under this Agreement shall in any way affect or impair the rights of any other Senior Lender and the obligations of the Subordinated Lender under this Agreement. 
 11. No delay on the part of any Senior Lender in the exercise of any right or remedy shall operate as a waiver of such right or remedy, and no single or
partial exercise by the Senior Lenders of any right or remedy shall preclude other or further exercise of such right or remedy or the exercise of any other right or remedy; nor shall any modification or waiver of any of the provisions of this
Agreement be binding upon any Senior Lender except as expressly set forth in a writing duly signed and delivered by each of the Senior Lenders. For the purposes of this Agreement, Senior Liabilities shall have the meaning set forth in Section 1
above, notwithstanding any right or power of the Subordinated Lender or anyone else to assert any claim or defense as to the invalidity or unenforceability of any such obligation, and no such claim or defense shall affect or impair the agreements
and obligations of the Subordinated Lender under this Agreement. 
 12. This Agreement shall continue in full force and effect after the
filing of any petition (“Petition”) by or against the Company and/or any of its Subsidiaries under the United States Bankruptcy Code (the “Code”) and all converted or succeeding cases in respect thereof. All
references herein to the Company and/or Subsidiary shall be deemed to apply to the Company and such Subsidiary as debtor-in-possession and to a trustee for the Company and/or such Subsidiary. If the Company or any of its Subsidiaries shall become
subject to a proceeding under the Code, and if the Senior Lenders shall desire to permit the use of cash collateral or to permit or provide post-Petition financing from any Senior Lender (or an affiliate or a third party satisfactory to the Senior
Lenders) to the Company or any such Subsidiary under the Code, the Subordinated Lender agrees as follows: (1) adequate notice to the Subordinated Lender shall be deemed to have been provided for such consent or post-Petition financing if the
Subordinated Lender receives notice thereof three (3) business days (or such shorter notice as is given to the Senior Lenders) prior to the earlier of (a) any hearing on a request to approve such post-petition financing or (b) the
date of entry of an order approving same and (2) no objection will be raised by the Subordinated Lender to any such use of cash collateral or such post-Petition financing from any Senior Lender (or an affiliate of the Senior Lender).

 13. This Agreement shall be binding upon the Subordinated Lender and upon the heirs, legal representatives, successors and assigns of the
Subordinated Lender and the successors and assigns of the Subordinated Lender. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall be deemed to constitute one
agreement. It is understood and agreed that if facsimile copies of this Agreement bearing facsimile signatures are exchanged between the parties hereto, such copies shall in all respects have the same weight, force and legal effect and shall be
fully as valid, binding, and enforceable as if such signed facsimile copies were original documents bearing original signature. 
  

 4 

 14. So long as any of the Senior Liabilities shall remain outstanding, no Subordinated Lender shall
permit any of the documents, instruments and/or agreements entered into in connection with the Junior Liabilities to be amended, modified or otherwise supplemented without the prior written consent of the Senior Lenders. 
 15. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED, INTERPRETED AND ENFORCED ACCORDING TO, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO
PRINCIPLES OF CONFLICT OF LAWS PROVISIONS THEREOF AND SHALL BE BINDING UPON THE PARTIES HERETO AND THEIR RESPECTIVE SUCCESSORS AND ASSIGNS. ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT SHALL BE BROUGHT ONLY IN THE
STATE COURTS OF NEW YORK OR IN THE FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK; PROVIDED, HOWEVER, THAT THE SENIOR LENDER MAY CHOOSE TO WAIVE THIS PROVISION AND BRING AN ACTION OUTSIDE THE STATE OF NEW YORK. The individuals executing this
Agreement on behalf of the Subordinated Lender agree to submit to the jurisdiction of such courts and waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorneys’ fees and costs. Wherever
possible each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be
ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. 
 [signature page follows] 
  

 5 

 IN WITNESS WHEREOF, this Agreement has been made and delivered this 19th day of September 2008.

  

			
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	  

	Name:	 	Francis E. O’Donnell, Jr., M.D.
	Title:	 	Chairman & CEO

 [Signatures Continued on Next Page] 

			
	SENIOR LENDER:
	
	  

		
	By:	 	  

	Name:	 	
	Title:	 	

 [Signatures Continued on Next Page] 

 Acknowledged and Agreed to by: 
  

			
	BIOVEST INTERNATIONAL, INC.
		
	By:	 	  

	Name:	 	Steven Arikian, M.D.
	Title:	 	Chairman & CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]